Published in Melanoma Res on June 01, 2013
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 1.21
Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 1.15
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys (2014) 1.03
Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res (2014) 0.99
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
Targeted therapies in brain metastases. Curr Treat Options Neurol (2014) 0.93
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer (2015) 0.88
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res (2015) 0.85
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med (2015) 0.83
Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol (2014) 0.82
Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol (2016) 0.82
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81
The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. Oncologist (2016) 0.79
Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Rep Pract Oncol Radiother (2015) 0.77
The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res (2016) 0.76
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother (2016) 0.75
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer J (2017) 0.75
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci (2016) 0.75
Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. Oncologist (2017) 0.75
History and current state of immunotherapy in glioma and brain metastasis. Ther Adv Med Oncol (2017) 0.75
Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol (2017) 0.75
Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases. Cureus (2017) 0.75
Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res (2017) 0.75
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol (2006) 4.72
Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol (2004) 3.56
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2008) 2.83
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2005) 2.04
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91
Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol (2003) 1.83
High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol (2008) 1.61
Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg (2011) 1.52
Resection of insular gliomas: the importance of lenticulostriate artery position. J Neurosurg (2008) 1.48
A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest (2004) 1.46
A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.39
Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res (2012) 1.34
Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction. Int J Radiat Oncol Biol Phys (2008) 1.33
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2007) 1.33
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol (2010) 1.22
Mucosal melanomas: a case-based review of the literature. Oncologist (2010) 1.20
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn (2007) 1.18
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One (2010) 1.17
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys (2008) 1.17
Prevention and management of cerebrospinal fluid leak following vestibular schwannoma surgery. Laryngoscope (2004) 1.16
Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer (2008) 1.14
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol (2009) 1.11
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2012) 1.10
IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell Immunol (2005) 1.10
Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol (2012) 1.10
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med (2012) 1.06
Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. Int J Radiat Oncol Biol Phys (2006) 1.04
Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer (2009) 1.03
The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J Neuroimmunol (2005) 1.01
Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol (2011) 0.99
Histology-specific microRNA alterations in melanoma. J Invest Dermatol (2012) 0.99
Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol (2010) 0.99
Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res (2009) 0.97
Novel therapeutics for melanoma. Expert Rev Anticancer Ther (2009) 0.96
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol (2012) 0.96
Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys (2005) 0.96
Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol (2013) 0.96
Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol (2005) 0.95
Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med Phys (2006) 0.94
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer (2009) 0.93
Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res (2010) 0.92
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Invest New Drugs (2010) 0.91
Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes. Diabetes Metab Res Rev (2002) 0.91
Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer (2007) 0.91
A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial surgery. World Neurosurg (2011) 0.91
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2013) 0.90
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer (2010) 0.90
Auditory brainstem implantation in patients with neurofibromatosis type 2. Laryngoscope (2004) 0.90
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res (2008) 0.89
Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg (2013) 0.89
Accuracy and feasibility of cone-beam computed tomography for stereotactic radiosurgery setup. Med Phys (2007) 0.89
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas. Am J Clin Oncol (2002) 0.88
Retrolabyrinthine craniectomy: the unsung hero of skull base surgery. Skull Base (2004) 0.88
Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol (2012) 0.87
Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg (2011) 0.87
Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. J Autoimmun (2004) 0.87
Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery (2006) 0.86
Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Detection of third and sixth cranial nerve palsies with a novel method for eye tracking while watching a short film clip. J Neurosurg (2014) 0.84
Importance of MR technique for stereotactic radiosurgery. Neuro Oncol (2003) 0.84
Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol (2009) 0.83
Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. J Transl Med (2008) 0.83
Update on vaccines for high-risk melanoma. Curr Treat Options Oncol (2014) 0.83
Targeted therapies for metastatic melanoma. Dermatol Clin (2012) 0.82
A panoramic view of the skull base: systematic review of open and endoscopic endonasal approaches to four tumors. Pituitary (2014) 0.81